Trial Profile
Phase II trial of VIPER [bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab] chemotherapy in relapsed and refractory diffuse large B-cell lymphoma (NHL) [non-Hodgkin's lymphoma].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Mesna (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Jan 2008 The expected completion date for this trial is now 1 Dec 2010.